Royal Bank of Canada »

Inhibikase Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.0k 663 1.51
2025-06-30 $16k 4.6k 3.53
2023-12-31 $3.0k 2.0k 1.50

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Amazon (AMZN)
Toronto Dominion Bk Ont Com New (TD)
Rbc Cad (RY)
Bank Of Montreal Cadcom (BMO)
Bk Nova Cad (BNS)
Alphabet Cap Stk Cl A (GOOGL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Ishares Tr Russell 2000 Etf (IWM)

View all positions for Royal Bank of Canada

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
ADAR1 Capital Management
Siren
Perceptive Advisors
Commodore Capital
Vanguard Group
Nantahala Capital Management
Saturn V Capital Management
BlackRock
Blackstone Group
Stonepine Capital Management
Integral Health Asset Management
Ameriprise Financial

View all funds holding Inhibikase Therapeutics